Javier B. Szwarcberg
Known title: Chief Executive OfficerCIK: 0001903669
Associated companies
Transaction History
| SPRB | ▲ Buy | Grant | 266 | $1K | 6/30/2026 | View on chart |
| SPRB | ▲ Buy | Grant | 4,690 | $21K | 12/31/2025 | View on chart |
| SPRB | ▲ Buy | Option Exercise | 1,196 | $0 | 12/15/2025 | View on chart |
| SPRB | ▲ Buy | Option Exercise | 1,480 | $0 | 12/15/2025 | View on chart |
| SPRB | ▼ Sell | Tax Withholding | 608 | $49K | 12/15/2025 | View on chart |
| SPRB | ▼ Sell | Tax Withholding | 752 | $61K | 12/15/2025 | View on chart |
| SPRB | ▲ Buy | Option Exercise | 4,950 | $0 | 12/11/2025 | View on chart |
| SPRB | ▼ Sell | Tax Withholding | 2,194 | $194K | 12/11/2025 | View on chart |
| SPRB | ▲ Buy | Option Exercise | 1,196 | $0 | 12/10/2025 | View on chart |
| SPRB | ▼ Sell | Tax Withholding | 428 | $37K | 12/10/2025 | View on chart |
| SPRB | ▲ Buy | Option Exercise | 4,784 | $0 | 10/20/2025 | View on chart |
| SPRB | ▼ Sell | Tax Withholding | 1,539 | $228K | 10/20/2025 | View on chart |
| SPRB | ▼ Sell | Tax Withholding | 39,605 | $15K | 12/16/2024 | View on chart |
| SPRB | ▲ Buy | Option Exercise | 89,700 | $0 | 12/16/2024 | View on chart |
| SPRB | ▼ Sell | Tax Withholding | 32,005 | $12K | 12/16/2024 | View on chart |
| SPRB | ▲ Buy | Option Exercise | 111,000 | $0 | 12/16/2024 | View on chart |
| SPRB | ▲ Buy | Option Exercise | 358,800 | $0 | 12/10/2024 | View on chart |
| SPRB | ▼ Sell | Tax Withholding | 128,020 | $69K | 12/10/2024 | View on chart |
| SPRB | ▲ Buy | Option Exercise | 111,000 | $0 | 12/15/2023 | View on chart |
| SPRB | ▼ Sell | Tax Withholding | 38,384 | $64K | 12/15/2023 | View on chart |
| SPRB | ▲ Buy | Grant | 20,000 | $20K | 6/30/2023 | View on chart |
| SPRB | ▲ Buy | Grant | 14,705 | $14K | 12/30/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Citizens Maintains $144 Target for Spruce Biosciences
Citizens Capital Markets has reaffirmed a market‑outperform rating for Spruce Biosciences and kept its $144 price target. The target sits well above the current trading level and within the company’s 52‑week range, suggesting upside potential. Analysts average a target of $148, with a wide range from $104 to $230. The stock’s RSI of 37.6 and a support level at $48.43 indicate it is not in overbought territory.
Citizens Maintains $144 Target for Spruce Biosciences. Citizens Capital Markets has reaffirmed a market‑outperform rating for Spruce Biosciences and kept its $144 price target. The target sits well above the current trading level and within the company’s 52‑week range, suggesting upside potential. Analysts average a target of $148, with a wide range from $104 to $230. The stock’s RSI of 37.6 and a support level at $48.43 indicate it is not in overbought territory.